Description: Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. The company's lead drug compound is Brilacidin, which is in Phase II study for the treatment of oral mucositis, inflammatory bowel disease, and acute bacterial skin and skin structure infection. It also develops Prurisol, a Phase IIb compound, which is in development for psoriasis; and Kevetrin, a lead anti-cancer compound for treating ovarian cancer. In addition, the company owns other candidates for treating diseases, including autism, arthritis, asthma, MS/ALS/Parkinson's, cancer, hypertensive emergency, and bacterial and fungal infections. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Beverly, Massachusetts.
Home Page: www.ipharminc.com
301 Edgewater Place
Wakefield,
MA
01880
United States
Phone:
978 921 4125
Officers
| Name | Title |
|---|---|
| Mr. Leo Ehrlich CPA | Chairman, CEO, CFO, Principal Accounting Officer & Sec. |
| Ms. Jane Harness M.S., MP, MS | Sr. VP of Clinical Sciences & Portfolio Management |
| Dr. W. James Alexander | Consultant |
| Mr. Jim Boeheim | Bus. Advisor |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9463 |
| Price-to-Sales TTM: | 557.1602 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 4 |